Successful Treatment of Human Monocytic Ehrlichiosis with Rifampin

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2016 English Publisher:Springer Science and Business Media LLCJournal:Cureus (issn: 2168-8184,

Copyright policy )

Authors: Abusaada, Khalid; Ajmal, Saira; Hughes, Laura;

doi: 10.7759/cureus.444

pmid: 26918212

pmc: PMC4744069

Successful Treatment of Human Monocytic Ehrlichiosis with Rifampin

- Summary
- Subjects
- Metrics

Abstract

Currently recommended treatment regimens for human monocytic ehrlichiosis (HME) include doxycycline or tetracycline. Antibiotic susceptibility studies demonstrate that rifampin has in vitro bactericidal activity against Ehrlichia. Case reports have suggested clinical response with rifampin treatment of human granulocytic anaplasmosis (HGA). We report the first case of HME successfully treated with rifampin.

Related Organizations

Mayo Clinic
United States
Mayo Clinic
United States
Florida Hospital Orlando
United States
Mayo Clinic
United States
AdventHealth East Orlando
United States

Keywords

Infectious Disease

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	5
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average